Office for Technology Commercialization

MET Targeted Fibronectin Protein Scaffolds

Technology #20150118

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Ben Hackel, Ph.D.
Assistant Professor, Department of Chemical Engineering and Materials Science, College of Science and Engineering
External Link (
Managed By
Raj Udupa
Technology Licensing Officer 612-624-3966
Patent Protection

Patent or Other Protection

Protein Scaffolds Bind to Hepatocyte Growth Factor Receptor

Non-immunoglobulin based fibronectin protein scaffolds that bind specifically to hepatocyte growth factor receptor (MET) can be used for molecular tumor imaging and targeted therapy. The non-naturally occurring protein scaffold includes a stable framework and loop region engineered to specifically bind MET. Its small size (94 amino acids) enables improved distribution and tissue and/or tumor penetration, which may result in more specific and sensitive cancer diagnoses and better outcomes. In addition, the technology shows potential for use as a targeted therapy.

MET Specific Imaging Applications

MET is an important cancer driver and biomarker, and while some therapeutics that target MET have been developed, no MET-specific imaging agents currently exist. The scaffolds developed in this technology provide non-invasive, whole body assessments of MET expression, with low toxicity and rapid clearance from the body. These scaffolds can enable early cancer detection, as well as better patient stratification.


  • Small size (94 amino acids)
  • Excellent physiological distribution
  • Penetrates tissue/tumors
  • May result in earlier diagnoses
  • Non-immunoglobulin based
  • Low toxicity and rapid clearance from the body
  • Non-invasive whole body assessment of MET expression


  • Patient stratification
  • Treatment monitoring
  • Early cancer diagnosis
  • Targeting for molecular imaging
  • Targeted therapy

Phase of Development - Proof of Concept